Over the last several years, the development of prostate-specific antigen (PSA) testing and technical refinements of anatomic radical prostatectomy have revolutionized the care of patients with prostate cancer. Serum PSA testing often allows early diagnosis of organ-confined prostate cancer. Anatomical radical prostatectomy has a high probability of completely eradicating these tumors, with minimal long-term morbidity. Use of PSA testing after therapy confirms the long-term ability of surgery to eradicate early-stage prostate cancer.
- digital rectal examination (DRE) screening
- prostate-specific antigen (PSA)
- transrectal ultrasound (TRUS)